RIKEN Center for Life Science Technologies

About CLST

Idea
greeting

Jobs at CLST

Access

Contact us

Links

Labs

Labs & Program

Center Director's Strategic Program RIKEN CLST-JEOL Collaboration Center

Publications

FANTOM

Technologies & Facilities

Technologies of CLST

Service of CLST

Radiosynthesis Database of PET Probes

Topics

  • Research

    Latest publications from CLST.
     

  • News

    Awards, agreements, and other news.

  • Events

    Upcoming and past events including seminars, symposiums, open days.

For Public

To let you know about our research, this area contains 4 types of information about CLST; “Article”, “Videos”, “Event” and “Study”.
At “Article”, you can read articles on interviews and lectures, and you can enjoy the videos about CLST at “Videos”. If you want to meet and talk directly with the researcher, “Visit” give you some information of such events. You can find more difficult contents to know about our research deeply at “Study”.
  • Article
  • Event
  • Videos
  • Study

Micro-Signaling Regulation Technology Unit Publications

Micro-Signaling Regulation Technology Unit

1

Visualizing Trimming Dependence of Biodistribution and Kinetics with Homo- and Heterogeneous N-Glycoclusters on Fluorescent Albumin.

Ogura A, Tahara T, Nozaki S, Morimoto K, Kizuka Y, Kitazume S, Hara M, Kojima S, Onoe H, Kurbangalieva A, Taniguchi N, Watanabe Y, Tanaka K.
Sci Rep.,(621797), (2016).
2

Metabolome analyses uncovered a novel inhibitory effect of acyclic retinoid on aberrant lipogenesis in a mouse diethylnitrosamine-induced hepatic tumorigenesis model

Qin XY, Tatsukawa H, Hitomi K, Shirakami Y, Ishibashi N, Shimizu M, Moriwaki H, Kojima S
Cancer Prev Res (Selected for the cover page image), 9(3), 205-214 (2016).
3

Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells

Shrestha R, Tatsukawa H, Shrestha R, Ishibashi N, Matsuura T, Kagechika H, Kose S, Hitomi K, Imamoto N, Kojima S
Cell Death Dis., 6(12), e2002 (2015).
4

CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors

Hashimoto K, Suzuki AM, Dos Santos A, Desterke C, Collino A, Ghisletti S, Braun E, Bonetti A, Fort A, Qin XY, Radaelli E, Kaczkowski B, Forrest AR, Kojima S, Samuel D, Natoli G, Buendia MA, Faivre J, Carninci P.
Genome Res, 25(12), 1812-1824 (2015).
5

L(59) TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice.

Hara M, Inoue I, Yamazaki Y, Kirita A, Matsuura T, Friedman SL, Rifkin DB, Kojima S
Fibrogenesis Tissue Repair., 8(17), (2015).
6

Carboxylic derivatives of vitamin K2 inhibit hepatocellular carcinoma cell growth through caspase/transglutaminase-related signaling pathways.

Qin XY, Fujii S, Shimizu A, Kagechika H, Kojima S.
J nutr sci vitaminol., 61(4), 285-290 (2015).
7

Hepatic fibrosis and angiogenesis after bile duct ligation are endogenously expressed vasohibin-1 independent.

Furutani Y, Shiozaki-Sato Y, Hara M, Sato Y, Kojima S.
Biochem Biophys Res Commun, 463(3), 384-388 (2015).
8

Eicosapentaenoic Acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.

Konuma K, Itoh M, Suganami T, Kanai S, Nakagawa N, Sakai T, Kawano H, Hara M, Kojima S, Izumi Y, Ogawa Y.
PLoS One, 10(3), e0121528 (2015).
9

Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression.

Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M, Sugiyama M, Kojima S, Tanaka Y, Mizokami M, Li J, Tong S, Wakita T.
J Biol Chem, 290(9), 5673-5684 (2015).
10

TGF-β LAP Degradation Products, a Novel Biomarker and Promising Therapeutic Target for Liver Fibrogenesis

Mitsuko Hara, Tomokazu Matsuura, Soichi Kojima
Innovative Medicine,, 317-325 (2015).
11

Control of TG functions depending on their localization.

Yutaka Furutani • Soichi Kojima
Transglutaminases,, 43-62 (2015).
12

LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis.

Hara M, Kirita A, Kondo W, Matsuura T, Nagatsuma K, Dohmae N, Ogawa S, Imajoh-Ohmi S, Friedman SL, Rifkin DB, Kojima S.
Springerplus, 3, 221 (2014).
13

Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β.

Sakata K, Eda S, Lee ES, Hara M, Imoto M, Kojima S.
Biochem Biophys Res Commun, 443(3), 950-956 (2014).
14

The Effect of Acyclic Retinoid on the Metabolomic Profiles of Hepatocytes and Hepatocellular Carcinoma Cells

Qin XY, Wei F, Tanokura M, Ishibashi N, Shimizu M, Moriwaki H, Kojima S.
PLoS One, 8(12), e82860 (2013).
15

HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor.

Sakata K, Hara M, Terada T, Watanabe N, Takaya D, Yaguchi S, Matsumoto T, Matsuura T, Shirouzu M, Yokoyama S, Yamaguchi T, Miyazawa K, Aizaki H, Suzuki T, Wakita T, Imoto M, Kojima S.
Sci Rep, 3, 3243 (2013).
16

Free fatty acids induce transglutaminase 2-dependent apoptosis in hepatocytes via ER stress-stimulated PERK pathways.

Kuo TF, Tatsukawa H, Matsuura T, Nagatsuma K, Hirose S, Kojima S.
J Cell Physiol, 227(3), 1130-1137 (2012).
17

New insights into the functions and localization of nuclear transglutaminase 2.

Kuo TF, Tatsukawa H, Kojima S.
FEBS J, 278(24), 4756-5767 (2011).
18

Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells.

Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, Moriwaki H, Kojima S.
Mol Cancer, 10, 4 (2011).
19

Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1.

Tatsukawa H, Fukaya Y, Frampton G, Martinez-Fuentes A, Suzuki K, Kuo TF, Nagatsuma K, Shimokado K, Okuno M, Wu J, Iismaa S, Matsuura T, Tsukamoto H, Zern MA, Graham RM, Kojima S.
Gastroenterology, 136(5), 1783-1795 (2009).

CLST was reorganized into three centers according to the RIKEN 4th Medium-Term Plan from April 1, 2018. For the latest information of Micro-Signaling Regulation Technology Unit, please visit the following websites.


> The webpage of Liver Cancer Prevention Research Unit, Center for Integrative Medical Sciences [http://www.ims.riken.jp/labo/74/index.html]


> If you continue to browse this site, click here.